Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide

Basit Öğe Kaydı
dc.authorscopusidMeral Beksaç / 56924887200
dc.authorwosidMeral Beksaç / JJK-2013-2023
dc.contributor.authorBeksaç, Meral
dc.contributor.authorGarcia, Esther Gonzalez
dc.contributor.authorDelimpasi, Sosana
dc.contributor.authorRobak, Pawel
dc.contributor.authorKarunanithi, Kamaraj
dc.date.accessioned2025-06-03T12:33:04Z
dc.date.available2025-06-03T12:33:04Z
dc.date.issued2024
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü
dc.description.abstractBelantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide
dc.identifier.citationBeksac, M., Garcia, E. G., Delimpasi, S., Robak, P., Karunanithi, K., De Arriba, F., ... & Dimopoulos, M. A. (2024). Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide. Blood, 144, 4731.
dc.identifier.doi10.1182/blood-2024-199282
dc.identifier.endpage4733
dc.identifier.issn0006-4971
dc.identifier.startpage4731
dc.identifier.uri10.1182/blood-2024-199282
dc.identifier.urihttps://hdl.handle.net/20.500.12713/7273
dc.identifier.volume144
dc.identifier.wosWOS:001416739600035
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.institutionauthorBeksaç, Meral
dc.institutionauthoridMeral Beksaç / 0000-0003-1797-8657
dc.language.isoen
dc.publisherAMER SOC HEMATOLOGY
dc.relation.ispartofBLOOD
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectHematology
dc.titleBelantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Temel Tıp Bilimleri Bölümü Diğer Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu